BUDGET REQUEST BY IC (SUMMARY TABLE)

| | FY 2023 | FY 2024 | FY 2025 |
|--|----------------------|-----------------|---------------------|
| (Dollars in Thousands) ¹ | Final ^{6,7} | CR ⁷ | President's |
| | Finai | CK | Budget ⁷ |
| NCI ² | \$7,317,241 | \$7,104,159 | \$9,287,141 |
| NHLBI | \$3,985,158 | \$3,982,345 | \$3,997,086 |
| NIDCR | \$520,138 | \$520,163 | \$521,695 |
| NIDDK ³ | \$2,444,548 | \$2,550,721 | \$2,569,991 |
| NINDS | \$2,809,418 | \$2,674,925 | \$2,833,827 |
| NIAID | \$6,561,652 | \$6,562,279 | \$6,581,291 |
| NIGMS ⁴ | \$3,239,679 | \$3,239,679 | \$3,249,375 |
| NICHD | \$1,747,784 | \$1,749,078 | \$1,766,415 |
| NEI | \$896,136 | \$896,549 | \$898,818 |
| NIEHS ⁵ | \$996,842 | \$997,014 | \$999,826 |
| NIA | \$4,412,090 | \$4,407,623 | \$4,425,295 |
| NIAMS | \$687,639 | \$685,465 | \$689,697 |
| NIDCD | \$534,330 | \$534,333 | \$535,929 |
| NIMH | \$2,341,653 | \$2,198,843 | \$2,548,662 |
| NIDA | \$1,663,365 | \$1,662,695 | \$1,668,343 |
| NIAAA | \$596,616 | \$595,318 | \$598,903 |
| NINR | \$197,671 | \$197,693 | \$198,263 |
| NHGRI | \$660,510 | \$663,200 | \$663,660 |
| NIBIB | \$440,625 | \$440,627 | \$441,944 |
| NIMHD | \$525,138 | \$524,395 | \$526,710 |
| NCCIH | \$170,277 | \$170,384 | \$170,894 |
| NCATS | \$923,323 | \$923,323 | \$926,086 |
| FIC | \$95,130 | \$95,162 | \$95,415 |
| NLM | \$495,314 | \$497,548 | \$526,796 |
| OD | \$3,066,208 | \$2,885,514 | \$3,044,455 |
| ARPA-H | \$1,500,000 | \$1,500,000 | \$1,500,000 |
| B&F | \$350,000 | \$350,000 | \$350,000 |
| Total, NIH Program Level | \$49,178,485 | \$48,609,035 | \$51,616,517 |
| Special Type 1 Diabetes Research (mandatory) | -\$141,450 | -\$250,000 | -\$260,000 |
| Mandatory Cancer Moonshot | | | -\$1,448,000 |
| PHS Program Evaluation | -\$1,412,482 | -\$1,412,482 | -\$2,018,482 |
| Interior Appropriation (Superfund Research) | -\$83,035 | -\$83,035 | -\$83,035 |
| Total, NIH Labor/HHS Budget Authority | \$47,541,518 | \$46,863,518 | \$47,807,000 |
| Pandemic preparedness (mandatory) (non-add) | | | \$2,690,000 |

¹ Includes funding derived by transfer from the NIH Innovation Account under the 21st Century Cures Act.

²Includes mandatory Cancer Moonshot proposal as shown later in the table

³ Includes Type 1 Diabetes mandatory funding with proposal as shown later in the table.

⁴ Includes Program Evaluation financing as shown later in the table.

⁵ Includes Interior appropriation for Superfund Research activities as shown later in the table.

⁶ Amounts reflect HIV/AIDS transfers across ICs under the authority of the Office of AIDS Research.

⁷ Reflects directive transfer of \$5.0 million from OD to the HHS Office of Inspector General.

APPROPRIATIONS ADJUSTMENT TABLES (FY 2023)

| | | | Permissive | | | | |
|--|--------------|-----------------|-----------------------|-----------------------|-----------------------|-----------------------|--------------|
| (Dollars in Thousands) | | | Transfer (NIH | | | | |
| | FY 2023 | Type 1 Diabetes | Innovation | OIG | HIV/AIDS | ARPA-H | FY 2023 |
| | Enacted | Sequestration | Account) ³ | Transfer ⁴ | Transfer ⁵ | Transfer ⁶ | Final |
| NCI | \$7,104,159 | | \$216,000 | | -\$2,918 | | \$7,317,241 |
| NHLBI | \$3,982,345 | | | | \$2,813 | | \$3,985,158 |
| NIDCR | \$520,163 | | | | -\$25 | | \$520,138 |
| NIDDK ¹ | \$2,450,721 | -\$8,550 | | | \$2,377 | | \$2,444,548 |
| NINDS | \$2,588,925 | | \$225,000 | | -\$4,507 | | \$2,809,418 |
| NIAID | \$6,562,279 | | | | -\$627 | | \$6,561,652 |
| NIGMS | \$3,239,679 | | | | | | \$3,239,679 |
| NICHD | \$1,749,078 | | | | -\$1,294 | | \$1,747,784 |
| NEI | \$896,549 | | | | -\$413 | | \$896,136 |
| NIEHS ² | \$997,014 | | | | -\$172 | | \$996,842 |
| NIA | \$4,407,623 | | | | \$4,467 | | \$4,412,090 |
| NIAMS | \$685,465 | | | | \$2,174 | | \$687,639 |
| NIDCD | \$534,333 | | | | -\$3 | | \$534,330 |
| NIMH | \$2,112,843 | | \$225,000 | | \$3,810 | | \$2,341,653 |
| NIDA | \$1,662,695 | | | | \$670 | | \$1,663,365 |
| NIAAA | \$595,318 | | | | \$1,298 | | \$596,616 |
| NINR | \$197,693 | | | | -\$22 | | \$197,671 |
| NHGRI | \$663,200 | | | | -\$2,690 | | \$660,510 |
| NIBIB | \$440,627 | | | | -\$2 | | \$440,625 |
| NIMHD | \$524,395 | | | | \$743 | | \$525,138 |
| NCCIH | \$170,384 | | | | -\$107 | | \$170,277 |
| NCATS | \$923,323 | | | | | | \$923,323 |
| FIC | \$95,162 | | | | -\$32 | | \$95,130 |
| NLM | \$497,548 | | | | -\$2,234 | | \$495,314 |
| OD | \$3,740,514 | | -\$666,000 | -\$5,000 | -\$3,306 | | \$3,066,208 |
| B&F | \$350,000 | | | | | | \$350,000 |
| ARPA-H | \$0 | | | | | \$1,500,000 | \$1,500,000 |
| Total, NIH Program Level | \$47,692,035 | -\$8,550 | \$0 | -\$5,000 | \$0 | \$1,500,000 | \$49,178,485 |
| Less funds allocated from different sources: | | | | | | | |
| Mandatory Type 1 Diabetes Research | -\$150,000 | \$8,550 | | | | | -\$141,450 |
| PHS Program Evaluation | -\$1,412,482 | | | | | | -\$1,412,482 |
| Total, NIH Discretionary Budget Authority | \$46,129,553 | \$0 | \$0 | -\$5,000 | \$0 | \$1,500,000 | \$47,624,553 |
| Interior Budget Authority | -\$83,035 | | | | | | -\$83,035 |
| Total, NIH Labor/HHS Budget Authority | \$46,046,518 | \$0 | \$0 | -\$5,000 | \$0 | \$1,500,000 | \$47,541,518 |

¹Includes Type 1 Diabetes.

²Includes Superfund Research activity.

 $^{^3\}mbox{Reflects}$ redistribution of NIH Innovation account for the 21st Century Cures Act.

 $^{^4\}mathrm{Reflects}$ directive transfer of \$5.0 million from OD to the HHS Office of Inspector General.

 $^{^5 \}mbox{Reflects HIV/AIDS}$ transfers across ICs under the authority of the Office of AIDS Research.

 $^{^6 \}mbox{Reflects}$ transfer of \$1,500.0 million from HHS Office of the Secretary to NIH.

APPROPRIATIONS ADJUSTMENT TABLES (FY 2024)

| (Dollars in Thousands) | FY 2024 CR | Type 1 Diabetes | Cures Innovation Account | Permissive Transfer (NIH Innovation | OIG | ARPA-H | FY 2024 CR |
|--|--------------|-----------------|--------------------------------|---|-----------------------|-----------------------|--------------|
| | Enacted | Proposed | Limitation ³ | Account)4 | Transfer ⁵ | Transfer ⁶ | Operating |
| NCI | \$7,104,159 | | | | | | \$7,104,159 |
| NHLBI | \$3,982,345 | | | | | | \$3,982,345 |
| NIDCR | \$520,163 | | | | | | \$520,163 |
| NIDDK ¹ | \$2,450,721 | \$100,000 | | | | | \$2,550,721 |
| NINDS | \$2,588,925 | | | \$86,000 | | | \$2,674,925 |
| NIAID | \$6,562,279 | | | | | | \$6,562,279 |
| NIGMS | \$3,239,679 | | | | | | \$3,239,679 |
| NICHD | \$1,749,078 | | | | | | \$1,749,078 |
| NEI | \$896,549 | | | | | | \$896,549 |
| NIEHS ² | \$997,014 | | | | | | \$997,014 |
| NIA | \$4,407,623 | | | | | | \$4,407,623 |
| NIAMS | \$685,465 | | | | | | \$685,465 |
| NIDCD | \$534,333 | | | | | | \$534,333 |
| NIMH | \$2,112,843 | | | \$86,000 | | | \$2,198,843 |
| NIDA | \$1,662,695 | | | | | | \$1,662,695 |
| NIA A A | \$595,318 | | | | | | \$595,318 |
| NINR | \$197,693 | | | | | | \$197,693 |
| NHGRI | \$663,200 | | | | | | \$663,200 |
| NIBIB | \$440,627 | | | | | | \$440,627 |
| NIMHD | \$524,395 | | | | | | \$524,395 |
| NCCIH | \$170,384 | | | | | | \$170,384 |
| NCATS | \$923,323 | | | | | | \$923,323 |
| FIC | \$95,162 | | | | | | \$95,162 |
| NLM | \$497,548 | | | | | | \$497,548 |
| OD | \$3,740,514 | | -\$678,000 | -\$172,000 | -\$5,000 | | \$2,885,514 |
| B&F | \$350,000 | | | | | | \$350,000 |
| ARPA-H | \$0 | | | | | \$1,500,000 | \$1,500,000 |
| Total, NIH Program Level | \$47,692,035 | \$100,000 | -\$678,000 | \$0 | -\$5,000 | \$1,500,000 | \$48,609,035 |
| Less funds allocated from different sources: | | | | | | | |
| Mandatory Type 1 Diabetes Research 1 | -\$150,000 | -\$100,000 | | | | | -\$250,000 |
| PHS Program Evaluation | -\$1,412,482 | | | | | | -\$1,412,482 |
| Total, NIH Discretionary Budget Authority | \$46,129,553 | \$0 | -\$678,000 | \$0 | -\$5,000 | \$1,500,000 | \$46,946,553 |
| Interior Budget Authority | -\$83,035 | | | | | | -\$83,035 |
| Total, NIH Labor/HHS Budget Authority | \$46,046,518 | \$0 | -\$678,000 | \$0 | -\$5,000 | \$1,500,000 | \$46,863,518 |

¹Includes Type 1 Diabetes baseline and proposed.

²Includes Superfund Research activity.

 $^{^3}$ Reflects reduction in appropriation from the Cures Innovation Account as limited by fund balances.

 $^{^4\}mathrm{Reflects}$ redistribution of NIH Innovation account for the 21st Century Cures Act.

 $^{^5} Reflects \ directive \ transfer \ of $5.0 \ million \ from \ OD \ to \ the \ HHS \ Office \ of \ Inspector \ General.$

 $^{^6\}mbox{Reflects}$ transfer of \$1,500.0 million from HHS Office of the Secretary to NIH.

BUDGET MECHANISM TABLE

| (Dollars in Thousands) ^{1,2,3} | | Y 2023 Final ⁹ | F | Y 2024 CR ⁹ | | Y 2025 nt's Budget ⁹ | | Y 2025 +/- 023 Final |
|--|-------------|--|-------------|--|-------------|---|---------|-------------------------------------|
| (Donats in Thousands) | No. | Amount | No. | Amount | No. | Amount | No. | Amount |
| December Desirates | | | | | | | | |
| Research Projects: Noncompeting | 30,177 | \$17,975,116 | 31,389 | \$19,039,410 | 31,481 | \$19,444,480 | 1,304 | \$1,469,365 |
| 2 | (3,793) | 535,090 | (3,048) | 368,151 | (2,999) | 351,610 | (-794) | -183,480 |
| Administrative Supplements ³ Competing | 11,106 | \$6,783,224 | 9,739 | \$5,643,337 | 10,273 | \$6,069,919 | -833 | -\$713,305 |
| Subtotal, RPGs | 41,283 | \$25,293,430 | 41,128 | \$25,050,898 | 41,754 | \$25,866,009 | 471 | \$572,580 |
| SBIR/STTR | 1,893 | 1,287,467 | 1,845 | 1,256,967 | 1,882 | 1,275,239 | -11 | -12,227 |
| Research Project Grants | 43,176 | \$26,580,896 | 42,973 | \$26,307,866 | 43,636 | \$27,141,249 | 460 | \$560,352 |
| | | , ,,,,,,,,, | , | , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | ., | , , , , , | | , , , , , , |
| Research Centers: | 4 0 4 5 | | 4.04 | | | | | **** |
| Specialized/Comprehensive | 1,045 | \$2,271,984 | 1,065 | \$2,317,655 | 1,119 | \$2,480,487 | 74 | \$208,504 |
| Clinical Research | 57 | 328,369 | 36 | | 24 | 198,750 | -33 | -129,619 |
| Biotechnology | 40 | 64,909 | 40 | 65,869 | 30 | 42,739 | -10 | -22,171 |
| Comparative Medicine | 49 | 137,280 | 47 | 131,225 | 47 | 130,065 | -2 | -7,214 |
| Research Centers in Minority Institutions | 23 1,214 | 78,613 \$2,881,155 | 23 1,211 | 79,164 \$2,852,909 | 23 1,243 | 79,164 \$2,931,206 | 0 29 | \$50,051 |
| Research Centers | 1,214 | \$2,001,133 | 1,211 | \$2,832,909 | 1,243 | \$2,931,200 | 29 | \$30,031 |
| Other Research: | | | | | | | | |
| Research Careers | 5,043 | \$928,335 | 5,030 | \$935,151 | 5,048 | \$945,157 | 5 | \$16,822 |
| Cancer Education | 83 | 23,219 | 82 | 22,837 | 82 | 22,837 | -1 | -382 |
| Cooperative Clinical Research | 269 | 485,641 | 245 | 485,100 | 436 | 1,008,525 | 167 | 522,884 |
| Biomedical Research Support | 126 | 111,657 | 120 | 103,257 | 47 | 54,321 | -79 | -57,336 |
| Minority Biomedical Research Support | 154 | 55,759 | 86 | 37,745 | 30 | 25,523 | -124 | -30,236 |
| Other | 2,536 | 1,732,101 | 2,457 | 1,605,568 | 2,764 | 1,861,395 | 228 | 129,294 |
| Other Research | 8,211 | \$3,336,712 | 8,020 | \$3,189,658 | 8,407 | \$3,917,757 | 196 | \$581,046 |
| Total Research Grants | 52,601 | \$32,798,763 | 52,204 | \$32,350,433 | 53,286 | \$33,990,212 | 685 | \$1,191,449 |
| Ruth L Kirchstein Training Awards: | FTTPs | | FTTPs | | FTTPs | | FTTPs | |
| Individual Awards | 3,968 | \$191,272 | 4,113 | \$200,800 | 4,122 | \$203,304 | 154 | \$12,032 |
| Institutional Awards | 13,469 | 793,060 | 13,812 | 820,640 | 13,800 | 830,904 | 331 | 37,844 |
| Total Research Training | 17,437 | \$984,331 | 17,925 | \$1,021,440 | 17,922 | \$1,034,208 | 485 | \$49,876 |
| - | | | | | | | | |
| Research & Development Contracts | 2,745 | \$4,032,891 | 2,623 | \$3,857,225 | 2,933 | \$4,582,467 | 188 | \$549,576 |
| (SBIR/STTR) (non-add) ³ | (101) | (75,193) | (79) | (61,364) | (166) | (130,942) | (65) | (55,750) |
| | | | | | | | | |
| Intramural Research | | \$5,046,199 | | \$5,133,445 | | \$5,274,376 | | \$228,177 |
| Research Management & Support | | 2,331,451 | | 2,442,336 | | 2,689,558 | | 358,107 |
| SBIR Admin (non-add) ³ | | (10,098) | | (10,881) | | (11,287) | | (1,188) |
| | | | | | | | | |
| Office of the Director - Appropriation ^{3,4} | | (3,066,208) | | (2,885,514) | | (3,044,455) | | (-21,753) |
| Office of the Director - Other | | 2,021,814 | | 1,841,120 | | 2,062,661 | | 40,847 |
| ORIP (non-add) 3,4 | | (309,393) | | (309,393) | | (259,393) | | (-50,000) |
| Common Fund (non-add) ^{3,4} | | (735,001) | | (735,001) | | (722,401) | | (-12,600) |
| | | 4 #00 000 | | 4 500 000 | | 4 500 000 | | |
| ARPA-H | | 1,500,000 | | 1,500,000 | | 1,500,000 | | 0 |
| 5 | | 200.000 | | 200.000 | | 400.000 | | *** |
| Buildings and Facilities ⁵ | | 380,000 | | 380,000 | | 400,000 | | 20,000 |
| Appropriation ³ | | (350,000) | | (350,000) | | (350,000) | | (0) |
| E 4 D 4 D 67 | | 141 450 | | 250,000 | | 260,000 | | 110 550 |
| Type 1 Diabetes ^{6,7} | | -141,450 | | -250,000 | | -260,000 -1,448,000 | | -118,550 -1,448,000 |
| Mandatory Cancer Moonshot ⁶ | | 1 412 492 | | -1,412,482 | | -2,018,482 | | -1,448,000 |
| Program Evaluation Financing ⁶ | | -1,412,482 | | -1,412,482 | | -2,018,482 | | -000,000 |
| Subtotal, Labor/HHS Budget Authority | | \$47,541,518 | | \$46,863,518 | | \$47,807,000 | | \$265,482 |
| Interior Appropriation for Superfund Research | | | | 83,035 | | 83,035 | | 0 |
| | | 83.035 | | | | , | | Ü |
| | | 83,035 \$47,624,553 | | | | \$47,890,035 | | \$265,482 |
| Total, NIH Discretionary Budget Authority | | \$47,624,553 | | \$46,946,553 | | \$47,890,035 260,000 | | \$265,482 118,550 |
| Total, NIH Discretionary Budget Authority Type 1 Diabetes ⁷ | | | | | | 260,000 | | 118,550 |
| Total, NIH Discretionary Budget Authority Type 1 Diabetes ⁷ Mandatory Cancer Moonshot | | \$47,624,553 141,450 0 | | \$46,946,553 250,000 0 | | 260,000 1,448,000 | | 118,550 1,448,000 |
| Total, NIH Discretionary Budget Authority Type 1 Diabetes ⁷ | | \$47,624,553 | | \$46,946,553 | | 260,000 | | 118,550 |
| Total, NIH Discretionary Budget Authority Type 1 Diabetes ⁷ Mandatory Cancer Moonshot Total, NIH Budget Authority | | \$47,624,553 141,450 0 \$47,766,003 | | \$46,946,553 250,000 0 \$47,196,553 | | 260,000 1,448,000 \$49,598,035 | | 118,550 1,448,000 \$1,832,032 |

See footnotes on following page.

Budget Mechanism Table Footnotes.

- Subtotal and Total numbers may not add due to rounding.
- ² Includes 21st Century Cures Act funding and excludes supplemental financing.
- ³ Numbers in italics and brackets are non-add.
- 4 Number of grants and dollars for the Common Fund and ORIP components of OD are distributed by mechanism and are noted here as non-adds. Office of the Director Appropriation is the non-add total of these amounts and the funds accounted for under OD Other.
- ⁵ Includes B&F appropriation and monies allocated pursuant to appropriations acts provisions such that funding may be used for facilities repairs and improvements at the NCI Federally Funded Research and Development Center in Frederick, Maryland.
- 6 Number of grants and dollars for mandatory Type 1 Diabetes (T1D), mandatory Cancer Moonshot, and Program Evaluation financing are distributed by mechanism above; therefore, T1D and Program Evaluation financing amounts are deducted to provide subtotals for Labor/HHS Budget Authority.
- Amount in FY 2023 reflect a reduction of \$8.550 million for Budget Control Act sequestration. FY2024 reflects annualized CR level of \$150.0 million plus \$100.0 million reauthorization proposal.
- 8 The FY 2025 budget also provides \$20 billion in mandatory funding across HHS for pandemic preparedness, which is reflected in the Public Health and Social Services Emergency Fund chapter. Of this total, NIH will receive \$2,690 million.
- ⁹ Reduced by a transfer of \$5.0 million from OD to the HHS Office of Inspector General.

BUDGET AUTHORITY BY OBJECT CLASS INCLUDING TYPE 1 DIABETES

FY 2025 Budget Authority by Object Class Including Type 1 Diabetes Funds ¹ (Dollars in Thousands)

| Object Classes | FY 2024 CR ² | FY 2025 President's Budget |
|--|----------------------------|---------------------------------------|
| Personnel Compensation | | |
| Full-Time Permanent (11.1) | \$1,425,949 | \$1,513,140 |
| Other Than Full-Time Permanent (11.3) | \$695,364 | \$721,376 |
| Other Personnel Compensation (11.5) | \$90,590 | \$94,566 |
| Military Personnel (11.7) | \$20,074 | \$21,093 |
| Special Personnel Services Payments (11.8) | \$267,072 | \$273,196 |
| Subtotal, Personnel Compensation (11.9) | \$2,499,048 | \$2,623,372 |
| Civilian Personnel Benefits (12.1) | \$843,784 | \$888,253 |
| Military Personnel Benefits (12.2) | \$4,051 | \$4,274 |
| Benefits to Former Personnel (13.0) | \$0 | \$0 |
| Total Pay Costs | \$3,346,883 | \$3,515,899 |
| Travel & Transportation of Persons (21.0) Transportation of Things (22.0) | \$49,278 \$8,360 | \$49,861 \$8,484 |
| Rental Payments to GSA (23.1) | \$37,104 | \$42,791 |
| Rental Payments to Others (23.2) | \$4,756 | \$5,621 |
| • | | |
| Communications, Utilities & Misc. Charges (23.3) | \$11,763 | \$14,208 \$322 |
| Printing & Reproduction (24.0) Consultant Services (25.1) | \$311 \$1,523,875 | \$1,601,937 |
| | | |
| Other Services (25.2) Purchase of Goods and Services from Government Accounts (25.3) | \$1,490,979 \$3,559,924 | \$1,546,434 \$3,702,055 |
| Operation & Maintenance of Facilities (25.4) | \$53,089 | |
| R&D Contracts (25.5) | | \$54,720 |
| ` / | \$2,891,558 | \$2,917,185 |
| Medical Care (25.6) Operation & Maintenance of Equipment (25.7) | \$44,016 \$253,423 | \$45,753 \$263,191 |
| | \$253,423 | · · · · · · · · · · · · · · · · · · · |
| Subsistence & Support of Persons (25.8) Subtotal Other Contractual Services (25.0) | \$9,816,865 | \$10,121,275 |
| · · · | \$260,592 | \$10,131,275 \$279,376 |
| Supplies & Materials (26.0) | | · · |
| Equipment (31.0) | \$156,519 | \$156,210 |
| Land and Structures (32.0) | \$330,762 | \$318,005 |
| Investments & Loans (33.0) | \$0 | \$0 |
| Grants, Subsidies & Contributions (41.0) | \$33,089,042 | \$33,543,660 |
| Insurance Claims & Indemnities (42.0) | \$0 \$1,284 | \$0 |
| Interest & Dividends (43.0) | | \$1,288 |
| Refunds (44.0) | \$0 | \$0 |
| Subtotal Non-Pay Costs | \$43,766,635 | \$44,551,101 |
| Total Budget Authority | \$47,113,518 | \$48,067,000 |

¹ Excludes the Superfund Research account under the jurisdiction of the Interior & Related Agencies Appropriations Subcommittee, Program Evaluation Financing, and Mandatory Cancer Moonshot. Includes Advanced Research Projects Agency for Health.

 $^{^2}$ FY 2024 amounts for Type 1 Diabetes program reflect annualized CR level of \$150.0 million plus \$100.0 million reauthorization proposal.

BUDGET AUTHORITY BY OBJECT CLASS INCLUDING SSF AND MF

FY 2025 Budget Authority by Object Class Including Service and Supply Fund and Management Fund¹

| | | FY 2025 |
|--|-------------------------|-----------------------|
| Object Classes | FY 2024 CR ² | President's Budget |
| Personnel Compensation | | |
| Full-Time Permanent (11.1) | \$1,922,096 | \$2,023,180 |
| Other Than Full-Time Permanent (11.3) | \$746,350 | \$773,790 |
| Other Personnel Compensation (11.5) | \$135,598 | \$140,835 |
| Military Personnel (11.7) | \$32,087 | \$33,668 |
| Special Personnel Services Payments (11.8) | \$276,654 | \$283,045 |
| Subtotal, Personnel Compensation (11.9) | \$3,112,785 | \$3,254,518 |
| Civilian Personnel Benefits (12.1) | \$1,060,037 | \$1,111,751 |
| Military Personnel Benefits (12.2) | \$4,919 | \$5,182 |
| Benefits to Former Personnel (13.0) | \$0 | \$0 |
| Total Pay Costs | \$4,177,741 | \$4,371,452 |
| | | |
| Travel & Transportation of Persons (21.0) | \$53,026 | \$53,729 |
| Transportation of Things (22.0) | \$10,905 | \$11,118 |
| Rental Payments to GSA (23.1) | \$111,839 | \$119,993 |
| Rental Payments to Others (23.2) | \$71,907 | \$74,988 |
| Communications, Utilities & Misc. Charges (23.3) | \$131,998 | \$138,427 |
| Printing & Reproduction (24.0) | \$314 | \$326 |
| Consultant Services (25.1) | \$754,054 | \$807,072 |
| Other Services (25.2) | \$3,086,862 | \$3,196,993 |
| Purchase of Goods and Services from Government Accounts (25.3) | \$901,071 | \$956,725 |
| Operation & Maintenance of Facilities (25.4) | \$207,452 | \$214,125 |
| R&D Contracts (25.5) | \$2,892,633 | \$2,918,290 |
| Medical Care (25.6) | \$73,219 | \$75,475 |
| Operation & Maintenance of Equipment (25.7) | \$517,687 | \$536,375 |
| Subsistence & Support of Persons (25.8) | \$0 | \$0 |
| Subtotal Other Contractual Services (25.0) | \$8,432,978 | \$8,705,055 |
| Supplies & Materials (26.0) | \$468,163 | \$493,408 |
| Equipment (31.0) | \$215,400 | \$216,869 |
| Land and Structures (32.0) | \$348,803 | \$336,569 |
| Investments & Loans (33.0) | \$0 | \$0 |
| Grants, Subsidies & Contributions (41.0) | \$33,089,103 | \$33,543,721 |
| Insurance Claims & Indemnities (42.0) | \$0 | \$0 |
| Interest & Dividends (43.0) | \$1,341 | \$1,347 |
| Refunds (44.0) | \$0 | \$0 |
| Subtotal Non-Pay Costs | \$42,935,777 | \$43,695,548 |
| Total Budget Authority | \$47,113,518 | \$48,067,000 |

¹Excludes the Superfund Research account under the jurisdiction of the Interior & Related Agencies Appropriations Subcommittee, Program Evaluation financing, supplemental appropriations, and mandatory Cancer Moonshot. Includes Advanced Research Projects Agency for Health.

 $^{^2}$ FY 2024 amounts for Type 1 Diabetes program reflect annualized CR level of \$150.0 million plus \$100.0 million reauthorization proposal.

FY 2025 Budget Authority by Object Class Including Type 1 Diabetes Funds¹

Salaries and Expenses / Administrative Expenses

| Object Classes | FY 2024 CR | FY 2025 President's Budget |
|---|---------------|-------------------------------|
| Personnel Compensation | | |
| Full-Time Permanent (11.1) | \$1,425,949 | \$1,513,140 |
| Other Than Full-Time Permanent (11.3) | \$695,364 | \$721,376 |
| Other Personnel Compensation (11.5) | \$90,590 | \$94,566 |
| Military Personnel (11.7) | \$20,074 | \$21,093 |
| Special Personnel Services Payments (11.8) | \$267,072 | \$273,196 |
| Subtotal, Personnel Compensation (11.9) | \$2,499,048 | \$2,623,372 |
| Civilian Personnel Benefits (12.1) | \$843,784 | \$888,253 |
| Military Personnel Benefits (12.2) | \$4,051 | \$4,274 |
| Benefits to Former Personnel (13.0) | \$0 | \$0 |
| Total Pay Costs | \$3,346,883 | \$3,515,899 |
| Travel & Transportation of Persons (21.0) | \$49,278 | \$49,861 |
| Transportation of Things (22.0) | \$8,360 | \$8,484 |
| Rental Payments to Others (23.2) | \$4,756 | \$5,621 |
| Communications, Utilities & Misc. Charges (23.3) | \$11,763 | \$14,208 |
| Printing & Reproduction (24.0) | \$311 | \$322 |
| Other Contractual Services | | |
| Consultant Services (25.1) ² | \$1,364,419 | \$1,441,807 |
| Other Services (25.2) | \$1,490,979 | \$1,546,434 |
| Purchase of Goods and Services from Government Accounts (25.3) ² | \$2,497,842 | \$2,610,118 |
| Operation & Maintenance of Facilities (25.4) ² | \$53,089 | \$54,720 |
| Operation & Maintenance of Equipment (25.7) | \$253,423 | \$263,191 |
| Subsistence & Support of Persons (25.8) | \$0 | \$0 |
| Subtotal Other Contractual Services | \$5,659,752 | \$5,916,270 |
| Supplies & Materials (26.0) | \$260,592 | \$279,376 |
| Subtotal Non-Pay Costs | \$5,994,812 | \$6,274,141 |
| Total Salaries and Expense / Administrative Costs | \$9,341,695 | \$9,790,040 |

¹ Excludes the Superfund Research account under the jurisdiction of the Interior & Related Agencies Appropriations Subcommittee,, Program Evaluation Financing and Mandatory Cancer Moonshot. Includes Advanced Research Projects Agency for Health.

 $^{^2}$ Excludes obligations from accounts (OC 25.1, 25.3 and 25.4) supporting Program Evaluations and Inter-agency Agreements related to the Research and Development Contracts mechanism.

DETAIL OF FULL-TIME EQUIVALENT EMPLOYMENT (FTE)

| | FY 2023 | FY 2024 | FY 2025 |
|--|---------|----------|----------|
| Institutes and Centers | Actual | Estimate | Estimate |
| NCI | 3,250 | 3,468 | 3,468 |
| NHLBI | 943 | 966 | 966 |
| NIDCR | 226 | 252 | 252 |
| NIDDK | 698 | 756 | 756 |
| NINDS | 650 | 713 | 729 |
| NIAID | 2,109 | 2,180 | 2,180 |
| NIGMS | 189 | 219 | 219 |
| NICHD | 561 | 602 | 624 |
| NEI | 272 | 291 | 300 |
| NIEHS | 634 | 685 | 685 |
| NIA | 584 | 650 | 800 |
| NIAMS | 241 | 250 | 258 |
| NIDCD | 134 | 140 | 140 |
| NIMH | 605 | 623 | 635 |
| NIDA | 419 | 445 | 470 |
| NIAAA | 204 | 238 | 238 |
| NINR | 84 | 106 | 106 |
| NHGRI | 356 | 385 | 385 |
| NIBIB | 123 | 160 | 160 |
| FIC | 54 | 61 | 61 |
| NIMHD | 94 | 210 | 210 |
| NCCIH | 94 | 110 | 115 |
| NCATS | 278 | 298 | 319 |
| NLM | 642 | 741 | 741 |
| OD | 1,134 | 1,217 | 1,241 |
| ARPA-H | 47 | 112 | 137 |
| Central Services: | | | |
| OD - CS | 871 | 911 | 916 |
| CC | 1,765 | 2,034 | 2,034 |
| CSR | 485 | 510 | 510 |
| CIT | 199 | 237 | 237 |
| ORS | 479 | 542 | 543 |
| ORF | 756 | 830 | 830 |
| Subtotal Central Services ¹ | 4,555 | 5,064 | 5,070 |
| PHS Trust Fund (non-add) ² | 4 | 4 | 4 |
| CRADA (non-add) ³ | 4 | 4 | 4 |
| Total | 19,180 | 20,942 | 21,265 |

¹ Reflects FTE associated with Central Services positions whose payroll costs are financed from the NIH Management Fund and the NIH Service and Supply Fund.

 $^{^2}$ PHS Trust Fund positions are incorporated within the IC's Direct-funded civilian FTE category and are treated as non-add values.

³ CRADA positions are distributed across multiple ICs and are treated as non-add values.

PROGRAMS PROPOSED FOR ELIMINATION

The FY 2025 request for the National Institutes of Health does not propose any programs for elimination.

PHYSICIAN'S COMPARABILITY ALLOWANCE WORKSHEET

| | | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|-----------|-----------|-----------------------|-----------|
| | | Actual | Actual | Estimate ¹ | Estimate |
| 1) Number of Physici | ans Receiving PCAs | 94 | 91 | 87 | 87 |
| 2) Number of Physici | ans with One-Year PCA | 1 | 3 | 2 | 2 |
| 3) Number of Physici | ans with Multi-Year PCA | 93 | 88 | 85 | 85 |
| 4) Average Annual P payment) | hysician Pay (without PCA | \$172,520 | \$179,325 | \$177,227 | \$182,189 |
| 5) Average Annual P | CA Payment | \$21,996 | \$22,918 | \$24,400 | \$25,083 |
| 6) Number of | Category I Clinical Position | | | | |
| Physicians | Category II Research Position | 93 | 91 | 87 | 87 |
| Receiving PCAs by Category (non-add) | Category III Occupational Health | | | | |
| | Category IV-A Disability | | | | |
| | Evaluation | | | | |
| | Category IV-B Health and Medical Admin. | 1 | 0 | 0 | 0 |

7) If applicable, list and explain the necessity of any additional physician categories designated by your agency (for categories other than I through IV-B). Provide the number of PCA agreements per additional category for the PY, CY and BY.

N/A

8) Provide the maximum annual PCA amount paid to each category of physician in your agency and explain the reasoning for these amounts by category.

Maximum annual PCA amounts for category II and IV-B vary based on grade level, amount of federal service and length of the PCA agreement. The monetary range is between \$4,000 and \$30,000. These flexible amounts are necessary to recruit and retain the caliber of physician needed to carry out the NIH mission which directly impacts the health of the

9) Explain the recruitment and retention problem(s) for each category of physician in your agency (this should demonstrate that a current need continues to persist). (Please include any staffing data to support your explanation, such as number and duration of unfilled positions and number of accessions and separations per fiscal year.)

NIH strives to make progress recruiting and retaining qualified physicians to the Federal service. However, due to competition and more lucrative compensation in the private sector it continues to be challenging. NIH consistently has had a high turnover rate for physicians. NIH physicians require unique and specialized qualifications that make it difficult to fill vacancies.

10) Explain the degree to which recruitment and retention problems were alleviated in your agency through the use of PCAs in the prior fiscal year. (Please include any staffing data to support your explanation, such as number and duration of unfilled positions and number of accessions and separations per fiscal year.)

In FY 2023, there were a total of 91 PCA recipients across NIH. In FY 2024 and beyond, as indicated by the decrease in recipients to-date relative to the prior year, the critical need continues to exist for highly qualified, specialized physicians to support the NIH mission. NIH still requires compensation flexibilities such as PCA to attract and retain qualified physicians.

11) Provide any additional information that may be useful in planning PCA staffing levels and amounts in your agency.

N/A

¹ FY 2024 data will be approved during the FY 2025 Budget cycle.

STATISTICAL DATA: DIRECT AND INDIRECT COSTS AWARDED

| | | | Percent | of Total | Percen | t Change |
|----------------------------------|------------------------|--------------------------|------------------------|--------------------------|------------------------|--------------------------|
| (Dollars in Thousands) | Direct Cost Awarded | Indirect Cost Awarded | Direct Cost Awarded | Indirect Cost Awarded | Direct Cost Awarded | Indirect Cost Awarded |
| FY 2013 | \$14,915,599 | \$5,755,617 | 72.2% | 27.8% | -6.7% | -6.9% |
| FY 2014 | \$15,568,553 | \$5,908,275 | 72.5% | 27.5% | 4.4% | 2.7% |
| FY 2015 | \$15,645,282 | \$6,020,843 | 72.2% | 27.8% | 0.5% | 1.9% |
| FY 2016 | \$16,791,158 | \$6,445,133 | 72.3% | 27.7% | 7.3% | 7.1% |
| FY 2017 ¹ | \$17,799,515 | \$6,838,801 | 72.2% | 27.8% | 6.0% | 6.1% |
| FY 2018 ¹ | \$19,599,758 | \$7,481,452 | 72.4% | 27.6% | 10.1% | 9.4% |
| FY 2019 ¹ | \$20,544,931 | \$7,953,747 | 72.1% | 27.9% | 4.8% | 6.3% |
| FY 2020 ¹ | \$21,765,222 | \$8,406,459 | 72.2% | 27.8% | 5.9% | 5.7% |
| FY 2021 ¹ | \$22,363,606 | \$8,620,853 | 72.2% | 27.8% | 2.8% | 2.6% |
| FY 2022 ^{1,a} | \$23,352,941 | \$8,993,865 | 72.2% | 27.8% | 4.4% | 4.3% |
| FY 2023 Final ^{1,a} | \$24,405,711 | \$9,377,383 | 72.2% | 27.8% | 4.5% | 4.3% |
| FY 2024 CR ^{1,a} | \$24,118,301 | \$9,253,572 | 72.3% | 27.7% | -1.2% | -1.3% |
| FY 2025 President's Budget 1,a,b | \$25,376,479 | \$9,647,941 | 72.5% | 27.6% | 5.2% | 4.3% |

Note: Data for fiscal years 2024 and later represent estimates and will change as actual data are received.

¹ Includes 21st Century Cures Act funding.

^a Figures do not include any funding related to ARPA-H.

^b Figures include funding related to the Cancer Moonshot.

RPGS – TOTAL NUMBER OF AWARDS AND FUNDING

| | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|--------------------------------|---------|---------|---------------------|---------------------|---------------------|---------------------|---------------------|------------|----------------------|-------------------|-------------------------|
| (Dollars in Thousands) | | | Actual ¹ | Actual 1,a | Final ^{1,a} | CR ^{1,a} | President's |
| | | | | | | | | | | | Budget ^{1,a,b} |
| No. of Awards: | | | | | | | | | | | |
| Competing | 9,540 | 10,364 | 10,123 | 11,116 | 11,020 | 11,373 | 11,258 | 11,333 | 11,106 | 9,739 | 10,273 |
| Noncompeting | 23,261 | 23,528 | 24,638 | 25,780 | 27,624 | 28,366 | 28,492 | 29,423 | 30,177 | 31,389 | 31,481 |
| Subtotal | 32,801 | 33,892 | 34,761 | 36,896 | 38,644 | 39,739 | 39,750 | 40,756 | 41,283 | 41,128 | 41,754 |
| SBIR/STTR | 1,578 | 1,689 | 1,807 | 2,034 | 2,023 | 1,832 | 1,863 | 1,840 | 1,893 | 1,845 | 1,882 |
| Total | 34,379 | 35,581 | 36,568 | 38,930 | 40,667 | 41,571 | 41,613 | 42,596 | 43,176 | 42,973 | 43,636 |
| Average Annual Cost: | | | | | | | | | | | |
| Competing RPGs | \$452 | \$484 | \$522 | \$527 | \$573 | \$559 | \$599 | \$588 | \$611 | \$579 | \$591 |
| Total RPGs ^X | 479 | 502 | 523 | 546 | 552 | 571 | 583 | 594 | 613 | 609 | 619 |
| Percent Change in Average Cost | | | | | | | | | | | |
| from Prior Year ^Y | | | | | | | | | | | |
| Competing RPGs | 8.2% | 7.2% | 7.8% | 1.0% | 8.7% | -2.4% | 7.2% | -1.8% | 3.8% | -5.1% | 2.0% |
| Total RPGs ^X | 8.0% | 4.8% | 4.0% | 4.4% | 1.1% | 3.5% | 2.1% | 2.0% | 3.1% | -0.6% | 1.7% |
| Average Length | | | | | | | | | | | |
| of Award in Years | 3.5 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 |

NOTE: Includes awards supported by the Common Fund program (for all years) and the Type 1 Diabetes mandatory account.

 $^{^{\}rm X}$ Includes Noncompeting RPGs and Administrative Supplements. Excludes SBIR/STTR awards.

Y Based on average costs in whole dollars.

¹ Includes 21st Century Cures Act funding.

^a Figures do not include any awards or funding related to ARPA-H.

^b Figures include awards or funding related to the Cancer Moonshot.

RPGS – SUCCESS RATES

| INSTITUTES & | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|--------------------------|---------|--------------------|--------------------|--------------------|--------------------|--------------------|----------------------|----------------------|-------------------|-------------------------|
| CENTERS ^{+,1,2} | | Final ³ | Final ^{3,a} | Final ^{3,a} | CR ^{3,a} | President's |
| CENTERS | | 222 | 222 | 222 | 222 | 2 2 2 2 2 2 | 11141 | 11141 | O.K | Budget ^{3,a,b} |
| NCI | 12.0% | 11.7% | 11.3% | 11.9% | 12.9% | 13.8% | 15.4% | 16.1% | 13.5% | 14.8% |
| NHLBI | 24.2% | 23.5% | 25.1% | 22.3% | 22.2% | 20.5% | 21.3% | 21.1% | 20.1% | 20.2% |
| NIDCR | 19.9% | 17.8% | 22.2% | 23.8% | 21.7% | 21.8% | 21.0% | 22.0% | 18.6% | 16.0% |
| NIDDK | 20.1% | 17.8% | 21.6% | 20.3% | 24.4% | 22.7% | 22.1% | 22.9% | 21.5% | 22.7% |
| NINDS | 19.8% | 17.7% | 22.4% | 20.4% | 23.7% | 20.2% | 22.1% | 21.6% | 16.8% | 15.4% |
| NIAID | 23.8% | 19.1% | 22.9% | 22.1% | 23.9% | 17.5% | 17.3% | 20.8% | 20.4% | 19.7% |
| NIGMS | 29.6% | 30.6% | 29.2% | 32.6% | 32.3% | 33.4% | 35.8% | 36.3% | 28.7% | 28.3% |
| NICHD | 13.2% | 16.1% | 18.4% | 19.5% | 18.0% | 18.4% | 17.3% | 18.8% | 18.3% | 19.1% |
| NEI | 25.7% | 24.9% | 26.7% | 28.4% | 29.6% | 24.8% | 25.6% | 26.2% | 23.6% | 23.6% |
| NIEHS | 14.2% | 15.0% | 17.1% | 14.8% | 14.2% | 14.4% | 16.7% | 15.1% | 14.0% | 21.5% |
| NIA | 22.8% | 26.6% | 28.9% | 29.2% | 25.8% | 24.2% | 25.3% | 24.0% | 10.4% | 10.4% |
| NIAMS | 16.0% | 17.0% | 16.7% | 17.1% | 18.0% | 17.6% | 18.4% | 17.8% | 14.2% | 12.6% |
| NIDCD | 26.7% | 24.4% | 27.1% | 25.2% | 24.2% | 24.0% | 25.0% | 26.9% | 24.9% | 24.8% |
| NIMH | 22.9% | 20.9% | 22.2% | 24.8% | 22.5% | 22.1% | 24.3% | 22.4% | 17.8% | 29.7% |
| NIDA | 15.4% | 19.7% | 19.4% | 17.5% | 16.9% | 14.7% | 19.4% | 22.1% | 15.9% | 17.5% |
| NIAAA | 18.8% | 22.0% | 26.7% | 20.9% | 21.4% | 17.1% | 27.1% | 30.5% | 20.1% | 22.7% |
| NINR | 9.0% | 8.9% | 10.3% | 9.3% | 10.8% | 12.6% | 15.4% | 16.9% | 20.7% | 19.2% |
| NHGRI | 25.6% | 23.9% | 28.0% | 19.2% | 21.8% | 24.7% | 25.1% | 22.0% | 21.3% | 20.3% |
| NIBIB | 14.6% | 13.0% | 16.8% | 18.3% | 19.8% | 17.2% | 21.5% | 17.7% | 15.6% | 16.3% |
| NIMHD | 19.3% | 21.5% | 10.7% | 7.5% | 7.9% | 11.2% | 17.2% | 18.8% | 9.6% | 16.2% |
| NCCIH | 13.9% | 16.7% | 20.3% | 12.5% | 11.6% | 11.1% | 14.8% | 14.4% | 9.6% | 9.2% |
| NCATS | 27.7% | 21.8% | 36.4% | 20.7% | 25.2% | 14.7% | 20.4% | 26.8% | 20.4% | 20.6% |
| FIC | 29.5% | 10.8% | 19.5% | 20.6% | 19.7% | 13.8% | 20.9% | 22.3% | 14.6% | 20.8% |
| NLM | 13.0% | 14.9% | 17.7% | 18.4% | 13.4% | 11.9% | 15.3% | 14.8% | 14.0% | 13.6% |
| ORIP & SEPA ^A | 18.8% | 16.5% | 17.8% | 34.2% | 29.6% | 25.9% | 27.1% | 34.0% | 34.0% | 34.0% |
| Common Fund | 12.6% | 11.8% | 10.9% | 11.0% | 9.5% | 8.8% | 11.8% | 14.6% | 9.2% | 9.8% |
| NIH | 19.1% | 18.7% | 20.3% | 20.1% | 20.7% | 19.1% | 20.8% | 21.4% | 17.5% | 18.4% |

⁺ Success Rates identified in FY 2024 and beyond are estimates, and will change as applications are received and selected for funding.

 $^{^{1}}$ Application success rates represent the percentage of applications that are awarded during the fiscal year.

² Includes Special type 1 Diabetes Research program administered by NIDDK. Excludes NIEHS Superfund Research and OD Other awards.

 $^{^3}$ Includes 21st Century Cures Act funding.

^A The SEPA program transitioned to NIGMS in FY 2017 from the NIH Office of Research Infrastructure Programs (ORIP).

^a Figures do not include any awards related to ARPA-H.

^b Figures include awards related to the Cancer Moonshot.

TOTAL R01 EQUIVALENT DATA FOR FIRST-TIME AND ESTABLISHED INVESTIGATORS

| R01 Equivalent Grants ^{1,2,3,4} | FY 2023 Final ^{5,a} | FY 2024 CR ^{5,a} | FY 2025 President's Budget ^{5,a,b} | |
|--|---------------------------------|------------------------------|---|--|
| Applications | | | | |
| Received | 35,072 | 37,819 | 38,441 | |
| Funded | 7,629 | 6,772 | 7,188 | |
| Total Investigators | | | | |
| Received | 32,547 | 35,329 | 36,324 | |
| Funded | 9,702 | 8,734 | 9,394 | |
| Established Investigators | | | | |
| Received | 20,454 | 22,126 | 22,849 | |
| Funded | 6,888 | 6,199 | 6,672 | |
| First-time Investigators | · | | · | |
| Received | 12,093 | 13,203 | 13,475 | |
| Funded | 2,814 | 2,535 | 2,722 | |

¹ R01 Equivalent Grants form a subset of all RPG awards. In FY 2023 they comprised roughly 69% of Funded Applications, 72% of Funded Total Investigators, 78% of Funded Established Investigators and 61% of Funded First-time Applicants. The year-to-year variation of these figures is about 2%, plus or minus.

² The ratio of total and funded applicants to applications and the proportion of total and funded first-time applicants are based on linear extrapolation of five years of the latest actual data.

³ Excludes applications and awards associated with reimbursable agreements and Superfund Research account.

⁴ Estimates for received applications reflect consolidations of Institute/Center validated refinements to linear extrapolation of five years of latest actual data. Funded application figures reflect the annual estimate identified in the New/Competing RPG line of mechanism budget table.

⁵ Includes 21st Century Cures Act funding.

^a Figures do not include any awards related to ARPA-H.

^b Figures include awards related to the Cancer Moonshot.

MF GENERAL STATEMENT

The NIH Management Fund (MF) was established on June 29, 1957, by Public Law 85-67. The MF was created to finance a variety of centralized support services and administrative activities that are required for the efficient and effective operation of all NIH programs and facilities. The services provided by the MF include a research hospital and outpatient clinic; receipt, review and referral of research and training grant applications, and general administrative support services. The MF is financed through offsetting collections from the NIH Institutes and Centers representing charges for services provided. Funds credited to the NIH Management Fund remain available for one fiscal year after the fiscal year in which they are deposited.

MF BUDGET AUTHORITY BY ACTIVITY

Budget Authority by Activity

| | FY 2023 Final | | FY 2024 CR | | FY 2025 President's Budget | | FY 2025 +/- FY 2023 Final | |
|--|---------------|-----------|------------|-----------|-------------------------------|-----------|------------------------------|----------|
| Extramural Research | FTE | Amount | FTE | Amount | FTE | Amount | FTE | Amount |
| <u>Detail</u> | | | | | | | | |
| Clinical Center | 1,765 | \$703,301 | 2,034 | \$730,047 | 2,034 | \$754,153 | 269 | \$50,853 |
| Center for Scientific Review, SREA | 485 | \$150,393 | 510 | \$156,128 | 510 | \$161,295 | 25 | \$10,903 |
| Office of Research Services, and Administrative services, support | | \$30 | | \$0 | | \$0 | | -\$30 |
| TOTAL | 2,250 | \$853,723 | 2,544 | \$886,175 | 2,544 | \$915,449 | 294 | \$61,726 |

MF BUDGET AUTHORITY BY OBJECT CLASS

| | | FY 2024 CR | FY 2025 President's Budget |
|----------|--|------------|-------------------------------|
| Total co | mpensable workyears: | | |
| | Full-time equivalent | 2,544 | 2,544 |
| | Full-time equivalent of overtime and holiday hours | 41 | 41 |
| | Average ES salary | \$220 | \$224 |
| | Average GM/GS grade | 11.6 | 11.6 |
| | Average GM/GS salary | \$127 | \$130 |
| | Average salary, Commissioned Corps (42 U.S.C. 207) | \$118 | \$123 |
| | Average salary of ungraded positions | \$134 | \$137 |
| | OBJECT CLASSES | FY 2024 CR | FY 2025 President's Budget |
| | Personnel Compensation | | |
| 11.1 | Full-Time Permanent | 229,533 | 235,960 |
| 11.3 | Other Than Full-Time Permanent | 42,160 | 43,340 |
| 11.5 | Other Personnel Compensation | 29,329 | 30,150 |
| 11.7 | Military Personnel | 7,639 | 7,997 |
| 11.8 | Special Personnel Services Payments | 9,424 | 9,688 |
| 11.9 | Subtotal Personnel Compensation | 318,085 | 327,135 |
| 12.1 | Civilian Personnel Benefits | 105,708 | 109,250 |
| 12.2 | Military Personnel Benefits | 862 | 902 |
| 13.0 | Benefits to Former Personnel | 0 | 0 |
| | Subtotal Pay Costs | 424,656 | 437,288 |
| 21.0 | Travel & Transportation of Persons | 2,308 | 2,373 |
| 22.0 | Transportation of Things | 804 | 827 |
| 23.1 | Rental Payments to GSA | 5 | 5 |
| 23.2 | Rental Payments to Others | 10 | 10 |
| 23.3 | Communications, Utilities & Misc. Charges | 2,272 | 2,363 |
| 24.0 | Printing & Reproduction | 0 | 0 |
| 25.1 | Consulting Services | 21,293 | 21,910 |
| 25.2 | Other Services | 125,534 | 130,806 |
| 25.3 | Purchase of Goods and Services from Government Accounts | 80,379 | 84,329 |
| 25.4 | Operation & Maintenance of Facilities | 6,480 | 6,642 |
| 25.5 | R&D Contracts | 347 | 353 |
| 25.6 | Medical Care | 24,707 | 25,078 |
| 25.7 | Operation & Maintenance of Equipment | 39,888 | 41,403 |
| 25.8 | Subsistence & Support of Persons | 0 | |
| 25.0 | Subtotal Other Contractual Services | 298,628 | 310,522 |
| 26.0 | Supplies & Materials | 129,729 | 133,621 |
| 31.0 | Equipment | 23,691 | 24,307 |
| 32.0 | Land and Structures | 4,012 | 4,072 |
| 33.0 | Investments & Loans | 0 | 0 |
| 41.0 | Grants, Subsidies & Contributions | 61 | 62 |
| 42.0 | Insurance Claims & Indemnities | 0 | |
| 43.0 | Interest & Dividends | 0 | 0 |
| 44.0 | Refunds | 0 | 0 |
| | Subtotal Non-Pay Costs | 461,519 | 478,161 |
| | Total Budget Authority by Object Class | 886,175 | |

 $^{^{\}rm 1}$ Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

MF DETAIL OF POSITIONS

| | FY 2023 | FY 2024 | FY 2025 |
|------------------------------------|-----------|-----------|-------------|
| | Final | CR | President's |
| GRADE | | | Budget |
| Total, ES Positions | 2 | 2 | 2 |
| Total, ES Salary | \$417,676 | \$439,395 | \$448,183 |
| GM/GS-15 | 116 | 134 | 134 |
| GM/GS-14 | 359 | 379 | 379 |
| GM/GS-13 | 352 | 407 | 407 |
| GS-12 | 529 | 613 | 613 |
| GS-11 | 360 | 417 | 417 |
| GS-10 | 33 | 38 | 38 |
| GS-9 | 77 | 91 | 91 |
| GS-8 | 73 | 81 | 81 |
| GS-7 | 152 | 174 | 174 |
| GS-6 | 38 | 42 | 42 |
| GS-5 | 10 | 12 | 12 |
| GS-4 | 5 | 6 | 6 |
| GS-3 | 6 | 7 | 7 |
| GS-2 | 3 | 4 | 4 |
| GS-1 | 0 | 0 | 0 |
| Subtotal | 2,113 | 2,405 | 2,405 |
| Commissioned Corps (42 U.S.C. 207) | | | |
| Assistant Surgeon General | 0 | 0 | 0 |
| Director Grade | 11 | 11 | 11 |
| Senior Grade | 9 | 9 | 9 |
| Full Grade | 11 | 11 | 11 |
| Senior Assistant Grade | 9 | 9 | 9 |
| Assistant Grade | 1 | 1 | 1 |
| Junior Assistant Grade | 0 | 0 | 0 |
| Subtotal | 41 | 41 | 41 |
| Ungraded | 220 | 220 | 220 |
| Total permanent positions | 2,131 | 2,421 | 2,421 |
| Total positions, end of year | 2,376 | 2,668 | 2,668 |
| Total full-time equivalent (FTE) | | | |
| employment, end of year | 2,250 | 2,544 | 2,544 |
| Average ES salary | 208,838 | 219,698 | 224,092 |
| Average GM/GS grade | 11.7 | 11.6 | 11.6 |
| Average GM/GS salary | 121,123 | 127,422 | 129,970 |

SSF GENERAL STATEMENT

The NIH Service and Supply Fund (SSF) was established on July 3, 1945, under 42 U.S.C. 231. The SSF was created to finance a variety of centralized research support services and administrative activities that are required for the efficient and effective operation of all NIH programs and facilities. The SSF provides a single means for consolidating the financing and accounting of business-type operations, including the sales of services and commodities to customers. The services provided through the SSF include mainframe computing, enterprise IT software planning and development, facilities engineering, planning, and design, facility use and maintenance including leased buildings, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, finance and accounting operations, government-wide contracting for IT, biomedical engineering, security, consolidated human resources, collaborative computer science research and other administrative support services. The SSF is financed through offsetting collections from the NIH Institutes and Centers representing charges for goods and services provided.

SSF BUDGET AUTHORITY BY ACTIVITY

Budget Authority by Activity

| | FY 2023 Final | | FY 2024 CR | | FY 2025 President's Budget | | FY 2025 +/- FY 2023 Final | |
|---|---------------|-------------|------------|-------------|-------------------------------|-------------|------------------------------|-----------|
| Extramural Research | FTE | Amount | FTE | Amount | <u>FTE</u> | Amount | FTE | Amount |
| <u>Detail</u> | | | | | | | | |
| Research Support and Administrative, OD, CC-CIF | 1,350 | \$1,613,795 | 1,453 | \$1,878,119 | 1,459 | \$1,936,998 | 109 | \$323,203 |
| Office of Research Facilities, Development & Operations | 756 | \$579,784 | 830 | \$697,569 | 830 | \$720,589 | 74 | \$140,805 |
| Center for Information Technology | 199 | \$527,929 | 237 | \$547,990 | 237 | \$566,107 | 38 | \$38,178 |
| TOTAL | 2,305 | \$2,721,508 | 2,520 | \$3,123,678 | 2,526 | \$3,223,694 | 221 | \$502,186 |

SSF BUDGET AUTHORITY BY OBJECT

Budget Authority by Object Class ¹

| | | FY 2024 CR | FY 2025 President's Budget |
|----------|--|--------------|-------------------------------|
| Total co | mpensable workyears: | | |
| | Full-time equivalent | 2,520 | 2,526 |
| | Full-time equivalent of overtime and holiday hours | 57 | 57 |
| | Average ES salary | \$223 | \$228 |
| | Average GM/GS grade | 12.1 | 12.1 |
| | Average GM/GS salary | \$131 | |
| | Average salary, Commissioned Corps (42 U.S.C. 207) | \$127 | · · |
| | Average salary of ungraded positions | \$161 | \$164 |
| | Treage stary of digraded positions | Ψ101 | · |
| | OBJECT CLASSES | FY 2024 CR | FY 2025 President's Budget |
| | Personnel Compensation | | |
| 11.1 | Full-Time Permanent | \$266,614 | \$274,079 |
| 11.3 | Other Than Full-Time Permanent | \$8,827 | · · |
| 11.5 | Other Personnel Compensation | \$15,680 | • |
| 11.7 | Military Personnel | \$4,374 | |
| 11.8 | Special Personnel Services Payments | \$157 | 1 |
| 11.9 | Subtotal Personnel Compensation | \$295,651 | |
| 12.1 | Civilian Personnel Benefits | \$110,545 | |
| 12.2 | Military Personnel Benefits | \$6 | • |
| 13.0 | Benefits to Former Personnel | \$0 | 1 |
| 15.0 | Subtotal Pay Costs | \$406,201 | |
| 21.0 | Travel & Transportation of Persons | \$1,440 | |
| 22.0 | Transportation of Things | \$1,742 | |
| 23.1 | Rental Payments to GSA | \$74,730 | • |
| 23.2 | Rental Payments to Others | \$67,141 | |
| 23.3 | Communications, Utilities & Misc. Charges | \$117,963 | • |
| 24.0 | Printing & Reproduction | \$3 | • |
| 25.1 | Consulting Services | \$96,060 | 1 |
| 25.2 | Other Services | \$1,470,349 | , , |
| 23.2 | Purchase of Goods and Services from Government | Ψ1, 470, 547 | φ1,517,755 |
| 25.3 | Accounts | \$382,447 | \$394,034 |
| 25.4 | Operation & Maintenance of Facilities | \$148,883 | \$152,763 |
| 25.5 | R&D Contracts | \$728 | \$752 |
| 25.6 | Medical Care | \$4,496 | \$4,645 |
| 25.7 | Operation & Maintenance of Equipment | \$224,376 | \$231,781 |
| 25.8 | Subsistence & Support of Persons | \$0 | \$0 |
| 25.0 | Subtotal Other Contractual Services | \$2,324,339 | |
| 26.0 | Supplies & Materials | \$77,842 | \$80,411 |
| 31.0 | Equipment | \$35,191 | \$36,352 |
| 32.0 | Land and Structures | \$14,029 | \$14,492 |
| 33.0 | Investments & Loans | \$0 | \$0 |
| 41.0 | Grants, Subsidies & Contributions | \$0 | \$0 |
| 42.0 | Insurance Claims & Indemnities | \$0 | \$0 |
| 43.0 | Interest & Dividends | \$57 | \$59 |
| 44.0 | Refunds | \$0 | |
| | Subtotal Non-Pay Costs | \$2,714,477 | \$2,805,428 |
| | Total Budget Authority by Object Class | \$3,123,678 | \$3,223,694 |

 $^{^{1}}$ Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

SSF DETAIL OF POSITIONS

| | FY 2023 | FY 2024 | FY 2025 |
|------------------------------------|-------------|-------------|-------------|
| | Final | CR | President's |
| GRADE | | | Budget |
| Total, ES Positions | 6 | 7 | 8 |
| Total, ES Salary | \$1,272,600 | \$1,561,904 | \$1,820,734 |
| GM/GS-15 | 119 | 130 | 131 |
| GM/GS-14 | 362 | 378 | 379 |
| GM/GS-13 | 758 | 803 | 805 |
| GS-12 | 336 | 372 | 372 |
| GS-11 | 131 | 144 | 144 |
| GS-10 | 10 | 10 | 10 |
| GS-9 | 101 | 126 | 126 |
| GS-8 | 42 | 50 | 49 |
| GS-7 | 99 | 110 | 112 |
| GS-6 | 10 | 15 | 15 |
| GS-5 | 7 | 11 | 13 |
| GS-4 | 9 | 14 | 12 |
| GS-3 | 12 | 11 | 11 |
| GS-2 | 6 | 6 | 6 |
| GS-1 | 4 | 7 | 7 |
| Subtotal | 2,006 | 2,187 | 2,192 |
| Commissioned Corps (42 U.S.C. 207) | | | |
| Assistant Surgeon General | 0 | 0 | 0 |
| Director Grade | 5 | 5 | 5 |
| Senior Grade | 5 | 5 | 5 |
| Full Grade | 8 | 8 | 8 |
| Senior Assistant Grade | 2 | 2 | 2 |
| Assistant Grade | 0 | 0 | 0 |
| Junior Assistant Grade | 0 | 0 | 0 |
| Subtotal | 20 | 20 | 20 |
| Ungraded | 323 | 352 | 352 |
| Total permanent positions | 2,305 | 2,481 | 2,502 |
| Total positions, end of year | 2,355 | 2,566 | 2,572 |
| Total full-time equivalent (FTE) | | | |
| employment, end of year | 2,305 | 2,520 | 2,526 |
| Average ES salary | 212,100 | 223,129 | 227,592 |
| Average GM/GS grade | 12.2 | 12.1 | 12.1 |
| Average GM/GS salary | 124,652 | 131,134 | 133,757 |

CYBERSECURITY

| Cyber Category | FY 2023 Final | FY 2024 CR | FY 2025 President's Budget | FY 2025 +/- FY 2023 |
|--|---------------|------------|----------------------------------|------------------------|
| Cyber Human Capital | 0.155 | 0.155 | 0.155 | |
| Planning Roles and Responsibilities | | | | |
| Sector Risk Assessment, Management, and Operations | | | | |
| Sector Coordination | | | | |
| Other NIST CSF Capabilities: | | | | |
| Detect | 25.450 | 27.990 | 28.040 | 2.590 |
| Identify | 65.140 | 71.640 | 71.782 | 6.642 |
| Protect | 99.921 | 109.913 | 110.110 | 10.189 |
| Recover | 10.030 | 11.041 | 11.070 | 1.040 |
| Respond | 27.482 | 30.230 | 30.283 | 2.801 |
| Total Cyber Request | 228.178 | 250.969 | 251.440 | 23.262 |
| Technology Ecosystems (non-add) | | | | |
| Zero Trust Implementation (non-add) | 0.042 | 0.042 | 0.023 | -0.019 |